Total Neoadjuvant Treatment for pMMR Locally Advanced Low Rectal Cancer: Anti-PD-1 Antibody With FOLFOXIRI and Preoperative Radiation Therapy

Total Neoadjuvant Treatment for pMMR Locally Advanced Low Rectal Cancer: Anti-PD-1 Antibody With FOLFOXIRI and Preoperative Radiation Therapy is a phase 2, interventional study registered as NCT06099951 by Sun Yat-sen University, with a registry enrolment figure of 53 participants, started 2023-11-01 and due to reach its primary completion in 2024-09-01. Interventions recorded: Serplulimab + FOLFOXIRI; Radiation therapy. Conditions listed: Colorectal Cancer. Primary outcome: Complete tumor response rate.. Colorectal eligibility wording from the registry: "* The pathological confirmation is rectal adenocarcinoma". No results are recorded here; the registry entry is the source.